24 May 2013
Keywords: USA, FDA, Post-marketing surveillance, Blue Spoon
Article | 15 January 2010
A strategy for the pharmaceutical industry to “sense and respond” to unpredictable effects associated with proactive risk surveillance by the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 January 2010
23 May 2013
© 2013 thepharmaletter.com